Compare LTRX & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTRX | CLLS |
|---|---|---|
| Founded | 1989 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.9M | 394.4M |
| IPO Year | 2000 | 2014 |
| Metric | LTRX | CLLS |
|---|---|---|
| Price | $7.06 | $1.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $10.58 | $5.33 |
| AVG Volume (30 Days) | ★ 1.0M | 171.9K |
| Earning Date | 11-04-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.52 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $120,899,000.00 | N/A |
| Revenue This Year | $14.67 | N/A |
| Revenue Next Year | $13.36 | $10.70 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.37 | $1.25 |
| 52 Week High | $8.75 | $5.48 |
| Indicator | LTRX | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 72.88 | 26.03 |
| Support Level | $5.09 | $1.31 |
| Resistance Level | $7.38 | $3.47 |
| Average True Range (ATR) | 0.37 | 0.14 |
| MACD | 0.17 | -0.01 |
| Stochastic Oscillator | 85.86 | 17.81 |
Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The company operates in a single operating segment: the development, marketing, and sale of industrial and enterprise IoT products and services. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic regions: the Americas; EMEA; and APJ. The Americas contribute the vast majority of total revenue.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.